VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, January 5, 2026
Stock Comparison
Hong Kong Exchanges and Clearing Limited vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Hong Kong Exchanges and Clearing Limited
0388.HK · Hong Kong Stock Exchange (HKEX)
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Hong Kong Exchanges and Clearing Limited's moat claims, evidence, and risks.
View 0388.HK analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Hong Kong Exchanges and Clearing Limited leads (92 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Hong Kong Exchanges and Clearing Limited has 4 segments (52.6% in Cash Markets); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Primary market structure: Monopoly vs Oligopoly. Pricing power: Moderate vs Moderate.
- Moat breadth: Hong Kong Exchanges and Clearing Limited has 9 moat types across 5 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Hong Kong Exchanges and Clearing Limited
Cash Markets
Exchange-based cash equities trading, clearing and settlement in Hong Kong (including Stock Connect cash markets)
Hong Kong (with Mainland China Connect linkage)
Brokers, banks, proprietary trading firms, and investors; listed issuers via primary/secondary markets
Exchange operator + clearing/settlement/depository operator
52.6%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
Hong Kong Exchanges and Clearing Limited strengths
Bristol-Myers Squibb Company strengths
Segment mix
Hong Kong Exchanges and Clearing Limited segments
Full profile >Cash Markets
Monopoly
Equity and Financial Derivatives
Monopoly
Commodities (LME and related)
Oligopoly
Data and Connectivity
Quasi-Monopoly
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.